107 results about "Pyrazinamide" patented technology

The invention relates to a preparation method of 6-fluoro-3-hydroxy-2-pyrazinamide, which is characterized by comprising the following steps: by using methyl 3-amino-2-pyrazinecarboxylate as the initial raw material, hydroxylating, esterifying, aminating, nitrifying, reducing and fluorizing to obtain the 6-fluoro-3-hydroxy-2-pyrazinamide. The preparation method of 6-fluoro-3-hydroxy-2-pyrazinamide has the advantages of easily purchased initial raw material, mild reaction conditions and high yield, is simple to operate, and is suitable for industrial production. The technical route is short, the operation is simple, and the technical conditions are easy to control. The yields of all the six reaction steps are high. The technical conditions are mild and easy to control. The invention is suitable for an industrial production device, and can operate stably.

A drug-resistance gene film chip for detecting mycobacterium tuberculosis is prepared by designing 54 probe spotting on a nylon film by aiming at the mutant sites of mycobacterium tuberculosis rpoB, kagG, embB, inhA, ahpC, gyrA, rrs, rpsL and pncA gene; 12 pairs of specific primers with biotin-labeled at 5' end are utilized; a sample DNA is subjected to triple PCR and amplified to form a large amount of gene fragment products with biotin; the amplified products and the probes on the film chip carry out specific hybridization; and then film washing, enzyme-linking and color reaction are carried out, thus preparing the chip. The gene film chip and the detection method thereof can detect the common gene mutations of the mycobacterium tuberculosis on the drug resistance of drugs such as isoniazid, rifampicin, streptomycin, ethambutol, pyrazinamide, quinolone and the like at one step, and are applicable to extracorporeal detection sputum sample, clinical isolation strains and mycobacterium tuberculosis multi-drug resistant gene in the organization sample.

The invention relates to a joint detection method for the drug resistance of mycobacterium tuberculosis and the pyrazinamide thereof in a clinical sample, comprising the following steps of: A, extracting DNA (deoxyribonucleic acid) in the sample; B, detecting the mycobacterium tuberculosis via fluorescent quantitative PCR (polymerase chain reaction) amplification for a tuberculosis genome segment containing total-length pyrazinamide enzyme genes (pncA); and C, detecting the drug resistance of pyrazinamide for the mycobacterium tuberculosis positive sample, wherein the steps for detecting the drug resistance of the pyrazinamide are as follows: 1, performing PCR reaction once by taking the fluorescent quantitative PCR product as a template, so as to add an in-vitro expression element; 2, adding the PCR product in a cell-free expression system, so as to express a pyrazinamide enzyme; and 3, comparing the pyrazinamide enzyme activity of the sample with a standard strain, so as to give the drug resistance result of pyrazinamide. According to the invention, joint detection for the drug resistance of mycobacterium tuberculosis and the pyrazinamide thereof in the sample is realized by combining fluorescent quantitative PCR amplification for pncA genes with the enzyme activity of the in-vitro expressed pyrazinamide enzyme, without the need of bacterial culture and a DNA sequencer.

The invention discloses a disease prevention and frost resistance fruit selenium-enriching nutritional agent for fruit trees and a preparation method of the disease prevention and frost resistance fruit selenium-enriching nutritional agent. The nutritional agent consists of the following components in part by weight: 20-40 parts of urea, 5-20 parts of ammonium dihydrogen phosphate, 35-65 parts of potassium dihydrogen phosphate, 15-35 parts of a boron fertilizer, 7-15 parts of a selenium fertilizer, 3-8 parts of salicylic acid, 1-3 parts of captopril, 4-10 parts of humic acid, 3-5 parts of pyrazinamide, 2-6 parts of metronidazole, 10-20 parts of paclobutrazol, 0.4-1 part of methylglutarate and 0.5-2 parts of disopyramide phosphate. The selenium-enriching nutritional agent disclosed by the invention has strong pertinence, can be used for solving multiple prominent problems existing in the planting of the fruit trees simultaneously, and has multiple effects such as disease prevention, rotten fruit prevention, frost resistance, dehiscent fruit prevention, fruit dropping prevention, fruit plumpness promotion, nutrition, selenium enrichment and the like.

The invention relates to a compound 6-fluorine-3-hydroxy-2-pyrazinamide synthetic method. The method comprises the following steps that a compound of a formula (IV) is used for preparing a compound of a formula (III) through amine ester exchange, the compound of the formula (III) is used for preparing a compound of a formula (II) through a fluorization reaction, and reaction equations are specified in the description, wherein the substituent group R is C1-4 alkoxy groups, X and Y are Cl or Br, and substituent groups X and Y can be identical or different. The preparation method for synthesizing a starting material 6-bromine (chlorin)-3-amino pyrazine formic ether is simple and low in cost; the synthetic line is simple and short, the method is simple, and key products can be obtained only through four-step reactions; reaction conditions of each step are mild, strong-corrosion and high-toxicity reagents are prevented from being adopted, and environmental pollution is reduced.

The invention discloses a myricetin pharmaceutical eutectic crystal and a preparation method thereof. The myricetin pharmaceutical eutectic crystal uses myricetin as the active pharmaceutical ingredients, uses theine, nicotinamide, pyrazinamide or 4-cyanopyridine as the precursors, and is a myricetin-theine eutectic crystal, a myricetin-nicotinamide eutectic crystal, a myricetin-pyrazinamide eutectic crystal or a myricetin-4-cyanopyridine eutectic crystal formed through intermolecular hydrogen bonds. The eutectic crystals are prepared by adopting the solution mediating crystal transformation method. The myricetin pharmaceutical eutectic crystal provided by the invention inherits the pharmacological activity of the myricetin; meanwhile, the solubleness, the dissolution rate and the stability of the myricetin pharmaceutical eutectic crystal are all significantly improved as compared with those of the myricetin; the myricetin pharmaceutical eutectic crystal facilitates the development of pharmaceutic preparation and the wide applications of the myricetin in the field of medicine.

The invention belongs to the field of chemical synthesis, and specifically relates to a preparation method for 6-fluoro-3-hydroxyl-2-pyrazinamide. According to the invention, 6-fluoro-3-hydroxyl-2-pyrazinamide is prepared by using 6-bromo-3-amino-2-pyrazinamide as a raw material through four reaction steps of amino protection, halogen replacement, deprotection and azidation. The invention has the following advantages: procurement or preparation of the raw material is convenient; the preparation method is simple and convenient to operate; and the prepared 6-fluoro-3-hydroxyl-2-pyrazinamide has high yield and is applicable to industrial production.

The invention provides a process for preparing a compound antituberculous preparation. Active ingredients are rifampicin and isoniazide and one of mixtures of isoniazide + pyrazinamide and isoniazide + pyrazinamide + gatifloxacin. The process includes that the rifampicin and a part of pharmaceutic adjuvant are sieved and mixed to be subjected to dry granulating, or rifampicin and any other active ingredients except for isoniazide are mixed with corresponding amount of pharmaceutic adjuvant to be subjected to the dry granulating, then the isoniazide, residual active ingredients and corresponding quantity of pharmaceutic adjuvant are sieved and mixed to be subjected to dry granulating or wet granulating, and finally the residual pharmaceutic adjuvant and two types of granules are mixed for a secondary tabletting to obtain the preparation. The process for preparing the compound antituberculous preparation has the advantages that by means of granulation step by step, the contact between the rifampicin and isoniazide is reduced, the amount of impurity hydrazone generated through reaction between the isoniazide and the rifampicin can be effectively reduced, the bioavailability of the isoniazide and the rifampicin is greatly improved, and the medication effectiveness and safety for mass patients with tuberculosis are guaranteed.

The invention discloses three carboxyl substituted aromatic compounds (shown as Formulas (1-3)), which can antagonize ribosome proteins S1 (RpsA) of a ribosome 30S small subunit, effectively inhibit the growth of mycobacterium tuberculosis and pyrazinamide-resistance mycobacterium tuberculosis and can be used for preparing drugs for treating pyrazinamide-resistance tuberculosis and tuberculosis (as shown in Description).

A pharmaceutical composition for treating tuberculotic diseases with no side effect/low side effect is provided by the present invention, which pharmaceutically effective amount of one or more compounds chosen from isoniazid, rifampin, pyrazinamide and ethambutol, and pharmaceutically effective amount of substances which can reduce the side effect of the antituberculosis agents.

The invention relates to a triple compound microsphere vascular targeted embolization sustained-release preparation containing an antituberculous drug as well as a preparation method and application of the preparation. The sustained-release agent comprises a carrier and drugs, wherein the drugs are coated with the carrier; the carrier is sodium alginate or chitosan, and the drugs are triple antituberculous compound drugs including rifampicin, isoniazid and pyrazinamide or moxifloxacin. The three antituberculous drugs are matrix drug solutions, the sodium alginate or chitosan is a carrier solution, the matrix drug solutions and the carrier solutiona are mixed to prepare a solution, the polymer solution containing drugs is dispersed into fogdrops with a certain diameter by adopting a high-voltage electrostatic droplet mode, and the fogdrops are sprayed into a solidifying liquid to prepare antituberculous drug microspheres under the action of calcium ions. The embolization sustained-release preparation can be used for treating tuberculosis, massive hemoptysis of pulmonary tuberculosis, tuberculosis cavity, renal tuberculosis, osteoarticular tuberculosis, genital tuberculosis, tuberculosis of thyroid gland, tuberculosis of cervical lymph nodes, tuberculosis of pericardium, tuberculosis of chest wall, pleural tuberculosis and other kinds of tuberculosis in a body.

The invention belongs to the technical field of medicine eutectic crystal, and concretely discloses an isoliquiritigenin pyrazinamide eutectic crystal and a preparation method thereof. According to the method, isoliquiritigenin and pyrazinamide are used as raw materials; a solvent auxiliary grinding method or a solvent suspension method is used for preparing the isoliquiritigenin pyrazinamide eutectic crystal. The obtained eutectic crystal has a novel crystal form, is favorable for novel preparation development, and promotes the application of the isoliquiritigenin to medicine clinics.

The invention discloses a small molecular inhibitor pyrazinamide (shortened as PZA) used in plant ethylene synthesis. The small molecular inhibitor pyrazinamide is characterized by being a specific inhibitor of ACC oxidase (ACO), and being capable of inhibiting conversion of an ethylene synthesis precursor ACC into ethylene in the plant ethylene synthesis; and the pyrazinamide has a structural formula shown as a figure in the abstract, and has the molecular weight of 123.12. The invention further provides a culture medium which contains the pyrazinamide and can inhibit the plant ethylene synthesis. The invention further provides application of the small molecular inhibitor pyrazinamide used in the plant ethylene synthesis to plant growth and development regulation and refreshment during plant transportation. The inhibitor pyrazinamide can obviously inhibit the plant ethylene synthesis, has a stronger effect than known ethylene synthesis inhibitors, and is convenient in popularization and application.

The invention discloses a method for simultaneously preparing pyrazinamide and isonicotinic acid through uncatalyzed hydrolysis of isonicotinic nitrile in a near critical water medium. The method comprises the following steps: adding deionized water and the isonicotinic nitrile into a high-pressure reaction kettle, stirring the mixture, raising the temperature to the boiling point at normal pressure, and opening an exhaust valve for 2 to 5 minutes; closing the exhaust valve, continuously raising the temperature to be between 200 and 300 DEG C, and hydrolyzing for 10 to 15 minutes; cooling hydrolysate, adjusting the pH value of the hydrolysate to be between 3 and 4, performing crystallization and filtration on the hydrolysate and obtaining coarse isonicotinic acid and filtrate; making the coarse isonicotinic acid subjected to hot-water dissolution, activated carbon decolorization, secondary crystallization and vacuum drying and obtaining isonicotinic acid products; adjusting the pH value of the filtrate to be between 8 and 9, performing crystallization and obtaining coarse pyrazinamide; and making the coarse pyrazinamide subjected to hot-water dissolution, activated carbon decolorization, secondary crystallization and vacuum drying and obtaining pyrazinamide products. The method does not add any catalyst during reaction, solves the pollution problem of acid and alkali catalyzed hydrolysis, has simple and green process, and has high purity and yield of the products.

The invention discloses a method for measuring pyrazinamide concentration in plasma through hygroplasm combination. A hygroplasm combination system is adopted for measurement. The method comprises thesteps that firstly, a to-be-measured sample is taken, a certain quantity of mixed organic solvent is added for conducting extraction twice, and after pretreatment, through chromatographic column separation, a mass spectrometry detector is used for detection. The method is quick to use, accurate, high in sensitivity and easy and convenient to operate, and the basis is provided for plasma concentration measurement of pyrazinamide. The linear range of a plasma standard curve is within 0.1-20 mug/mL, the within-run precision and between-run precision RSD are smaller than +/-15%, and the method issuitable for measurement of pyrazinamide concentration in the plasma.

The invention relates to a method for detecting the content of impurities in isoniazid or a medicinal composition thereof. The method comprises the following steps: 1, preparing an impurity reference substance solution, namely precisely weighing a proper amount of isonicotinic acid and an isonicotinic acid reference substance, dissolving with water, and quantitatively diluting to serve as isonicotinic acid and the isonicotinic acid reference substance solution; 2, preparing a test substance solution, namely weighing a proper amount of a test substance, adding water to dissolve isoniazid, diluting, filtering and taking subsequent filtrate as a test substance solution; 3, preparing a reference solution, namely precisely weighing the test substance solution, and diluting for 100 times to serve as a reference solution; and 4, carrying out a detection method, namely precisely weighing 10mu l of the impurity reference substance solution, 10mu l of the test sample solution and 10mu l of the reference solution respectively, respectively injecting into a liquid chromatograph, recording a chromatogram map, and calculating contents of isonicotinic acid, pyrazinamide and other impurities by adopting a peak area method according to the chromatogram map.

The present invention relates to a novel pyrazinamide derivative and more particularly a hydrated crystal of N, N'-(4-nitrogen heterocyclic-1, 7-heptyl) double-pyrazinamide compound, the structure and characteristic of which are mensurated by X-ray single-crystal diffraction, X-ray powder diffraction, thermogravimetric analysis, infrared spectrum, nuclear magnetism and element analysis; a molecular formula of the hydrated crystal is C8H18.50N3.50O5, the crystal belongs to the orthorhombic system, a space group is P2<1>2<1>2, unit cell parameters are that a is 11.164, b is 26.05, c is 4.582, and alpha, beta and gamma are equal to 90 degrees; unit cell size is that V is 1332.4 <3>. The preparation process of the hydrated crystal is simple; the crystal has high yield and purity and good stability. The pyrazinamide derivative can form a two-component crystal with the water absorption quantity of 29.56 percent, and the absorption of organic compound towards water molecule has the reversibility, which ensures that the compound can be applied to the recycling technology of worn atomic force microscopy silicon tips.

The invention belongs to the field of chemical synthesis and particularly relates to a reparation method of 6-bromine-3-hydroxyl-2-pyrazinamide. The method comprises the steps of converting 3-hydroxyl-2-pyrazinecarboxylic acid methyl ester which is taken as an initial material into 6-bromine-3-hydroxyl-2-pyrazinecarboxylic acid methyl ester, and then carrying out ammonolysis, so that the 6-bromine-3-hydroxyl-2-pyrazinamide can be prepared with high yield by simple and convenient operations. The preparation method has the advantages that the 3-hydroxyl-2-pyrazinecarboxylic acid methyl ester which is cheap in price, and convenient to purchase in markets is taken as the initial material, the method is simple and convenient and easy to implement, the selected solvent range is wide, a solvent is easy to remove, the yield is high, and the method can be applicable to industrial production.

The present invention relates to therapeutic combinations of anti-bacterial agents linezolid, bedaquiline and pretomanid, and optionally with pyrazinamide, in a short-course oral dosage regimen for the treatment of tuberculosis.

The invention discloses a method for simultaneously detecting five anti-tuberculosis drugs (including rifampin, rifabutin, Pyrazinamide, ethambutol and isoniazid) in blood plasma via a UPLC-MS/MS method. Blank blood plasma is weighed precisely, and added with standard working solutions mixed with a series of standard substances, standard working solutions of isotope internal standards in one to one correspondence are added, pre-treatment is carried out in a protein precipitation method, the UPLC-MS/MS method is used for analysis, chromatograms of different samples are obtained, and a standardcurve is established by taking the ratio of an object to be measured and the corresponding internal standard peak area as the abscissa and the concentration of the object to be measured as the ordinate; and blood plasma to be measured is weighed precisely, the standard working solutions of isotope internal standards in one to one correspondence are added, pre-treatment is carried out in the protein precipitation method, the UPLC-MS/MS method is used for analysis, chromatograms of different samples are obtained, and the concentration of the blood plasma sample is calculated by using the standard curve. The method is simple and rapid in operation and high in sensitivity, accuracy and precision, the matrix effect is low, and can satisfy requirements for monitoring the drug concentration of five anti-tuberculosis drugs in clinical application.

The invention relates to a preparation method of cefalonium. According to the preparation method, raw materials (cefalotin and pyrazinamide) react at a low temperature to obtain the product cefalonium. The preparation method particularly comprises the following steps: dissolving cefalotin acid into an organic acid, carrying out carboxyl protection by using a silanization protection reagent and then carrying out iodination reaction on reaction products and iodotrimethylsilane; then carrying out amination reaction on the reaction product from the former step and pyrazinamide; and finally carrying out deprotection by alcoholysis, regulating the pH value at a low temperature and crystalizing to obtain cefalonium. According to the preparation method of cefalonium, cefalotin acid is protected by the silanization protection reagent in an organic solvent and then reacts with iodotrimethylsilane; the reaction time is short, the reaction conditions are mild, the reaction is complete and no side reaction is almost generated; due to adoption of a mixed solvent crystallization method, the characteristics of high drying speed, light color and high yield can be achieved; in addition, the used solvent can be recycled and the amount of generated sewage can be reduced; therefore, the preparation method of cefalonium has remarkable economic and environmental benefits and facilitates industrial production.

The invention discloses a method for detecting an anti-tuberculosis drug in serum by an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The antitubercular drug comprises cycloserine (CYS), pyrazinamide (PZN), isoniazid (INZ), p-aminosalicylic acid (P-ASA), ethiisonicotinamide (ETN), ethambutol (ETB), clofazimine (CFM), bedaquiline (BDQ), rifampicin (RFP), rifbutine (RFB) and rifapentine (RFT). The method includes: detecting the content of the antituberculosis drug in the pretreated serum by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry method, performing quantifying by utilizing a mass spectrometry isotope internal standard method, establishing a calibration curve by taking the concentration ratio of the standard substance to the internal standard substance as an X axis and the peak area ratio of the standard substance to the internal standard substance as a Y axis, and calculating the concentration of the target drug in the serum; the method is high in sensitivity, strong in specificity and simple in pretreatment process, separation and detection of the anti-tuberculosis drugs in serum are completed within 5 min, and a simple and rapid detection method is provided for clinical concentration monitoring of the anti-tuberculosis drugs.

The invention provides a pyrazinamide tablet and a preparation method thereof. The pyrazinamide tablet is prepared from the following components in parts by weight: 250 parts of pyrazinamide, 24 partsof filler, 12 parts of saccharose, 18 parts of microcrystalline cellulose, 8 parts of hydroxypropylcellulose, 20 parts of 18% pulp starch, 2 parts of polysorbate-80, 1 part of lubricant, 4 parts of sodium carboxymethyl starch, and 1 part of binding agent. The pyrazinamide tablet prepared according to the preparation method overcomes the defects that in the prior art, the pyrazinamide tablet is prone to crushing in the preparation process and the tablet is out of shape, the finished product ratio and the tabletting speed of the pyrazinamide tablet are improved, and the production efficiency ofthe pyrazinamide tablet is remarkably improved.

The invention relates to a vascular targeting embolism sustained release agent of a triple compound microsphere for an antituberculosis drug, a preparation method and applications thereof. The sustained release agent comprises a carrier and a drug, wherein the drug is encapsulated by the carrier, the carrier is selected from sodium alginate or chitosan, and the drug is a triple compound antituberculosis drug which comprises rifampin, isoniazide and pyrazinamide or moxifloxacin. Three antituberculosis drugs are employed as matrixes of a drug solution, sodium alginate or chitosan is used as a carrier solution, and a prepared solution is obtained by mixing the drug solution and the carrier solution. A polymer solution having the drug is enabled to be dispersed into droplets with certain particle sizes and to be sprayed into a curing liquid through a method of high voltage electrostatic droplets, and thus the microsphere for the antituberculosis drug are prepared in the presence of calcium ions. The embolism sustained release agent can be used in the drug for treating pulmonary tuberculosis, pulmonary tuberculosis massive hemoptysis, cavitary pulmonary tuberculosis, renal tuberculosis, osteoarticular tuberculosis, genital tubercolosis, thyroid tuberculosis, tuberculosis of cervical lymph nodes, pericardial tuberculosis, chest-wall tuberculosis and other in-vivo tuberculosises.